RxDoctor Payments Data

Kristen Gurtner

Urology · New Orleans, LANPI 1962899633

Payments from drug & device makers

$4,455in general payments, 2019–2025

Across 158 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$684
  • Teleflex LLC$524
  • Sumitomo Pharma America, Inc.$357
  • Axonics, Inc.$350
  • Astellas Pharma US Inc$307
  • Boston Scientific$278
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,36798%
  • Education$882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,455 in reported general payments places this provider in the 60th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$76,124
Medicare patients
273
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron95$64,179
GemtesaVibegron54$31,910
Estradiol71$4,965
Tamsulosin Hcl338$3,404
Solifenacin Succinate33$1,532
Finasteride101$881
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$759
Silodosin18$681
Oxybutynin Chloride ErOxybutynin Chloride37$541
Alfuzosin Hcl ErAlfuzosin Hcl34$454
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim159$260
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen52$193
Phenazopyridine Hcl19$185
Ciprofloxacin Hcl51$184
Betamethasone Valerate11$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$307$64,17995 claims
Sumitomo Pharma America, Inc.Gemtesa$357$31,91054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 199 urology providers in Louisiana.

Other urology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →